Prognostic markers for the clinical course in the blood of patients with SARS-CoV-2 infection

Eur J Med Res. 2022 Nov 21;27(1):255. doi: 10.1186/s40001-022-00864-z.

Abstract

Background: The presentation of peptides and the subsequent immune response depend on the MHC characteristics and influence the specificity of the immune response. Several studies have found an association between HLA variants and differential COVID-19 outcomes and have shown that HLA genotypes are associated with differential immune responses against SARS-CoV-2, particularly in severely ill patients. Information, whether HLA haplotypes are associated with the severity or length of the disease in moderately diseased individuals is absent.

Methods: Next-generation sequencing-based HLA typing was performed in 303 female and 231 male non-hospitalized North Rhine Westphalian patients infected with SARS-CoV2 during the first and second wave. For HLA-Class I, we obtained results from 528 patients, and for HLA-Class II from 531. In those patients, who became ill between March 2020 and January 2021, the 22 most common HLA-Class I (HLA-A, -B, -C) or HLA-Class II (HLA -DRB1/3/4, -DQA1, -DQB1) haplotypes were determined. The identified HLA haplotypes as well as the presence of a CCR5Δ32 mutation and number of O and A blood group alleles were associated to disease severity and duration of the disease.

Results: The influence of the HLA haplotypes on disease severity and duration was more pronounced than the influence of age, sex, or ABO blood group. These associations were sex dependent. The presence of mutated CCR5 resulted in a longer recovery period in males.

Conclusion: The existence of certain HLA haplotypes is associated with more severe disease.

Keywords: CCR5; COVID-19; Chemokine receptor; Clinical course of the disease; HLA haplotypes; Neutralizing antibodies; Persistence; SARS-CoV-2.

MeSH terms

  • COVID-19* / genetics
  • Female
  • HLA-DQ Antigens / genetics
  • HLA-DRB1 Chains
  • Humans
  • Male
  • Prognosis
  • RNA, Viral
  • SARS-CoV-2

Substances

  • HLA-DQ Antigens
  • RNA, Viral
  • HLA-DRB1 Chains